Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyOverall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy

In an editorial accompanying the final results of the TOURMALINE-MM1 study, Drs. D’Souza and Lonial question whether overall survival (OS) is “still the gold standard for demonstrating the value of a novel agent in phase III trials early in the disease course given the current treatment landscape.”

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form